Retatrutide 10mg | NeuroPept Labs

Description Retatrutide (LY3437943) is a synthetic 39-amino acid research peptide studied as a triple receptor agonist targeting the GLP-1 (glucagon-like peptide-1), GIP (gastric inhibitory polypeptide), and glucagon receptors simultaneously. This triple-action receptor profile distinguishes it from single-target GLP-1 agonists and dual-target compounds such as tirzepatide, making it one of the most studied metabolic research peptides in preclinical and clinical investigation.   NeuroPept Labs supplies Retatrutide 10mg as a research-grade lyophilized peptide intended strictly for in vitro laboratory and analytical research use. All batches are manufactured under controlled synthesis conditions and verified through third-party analytical testing. COA validity can be confirmed at freedomdiagnosticstesting.com using the Accession Number, Client ID, or Search Code found in the product images.   Mechanism of Action (Research Overview)   Retatrutide exhibits agonist activity at three distinct receptor pathways:   GLP-1 Receptor (GLP-1R) stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, reduces gastric emptying, and modulates appetite signalling GIP Receptor (GIPR) augments insulin secretion post-meal and supports lipid clearance, complementing GLP-1R signalling for enhanced glycemic modulation Glucagon Receptor (GCGR) the key differentiator from dual agonists; glucagon receptor activation promotes hepatic fat metabolism, increases energy expenditure, and contributes to lipolysis and fatty acid oxidation   This combination is referred to in the research literature as “Triple G” receptor agonism and has demonstrated up to 24.2% mean weight reduction in Phase 2 obesity trials over 48 weeks.   Research Significance   Retatrutide is currently in Phase 3 clinical trials and is considered one of the most promising investigational compounds in metabolic research. Key areas of research interest include:   Metabolic dysfunction and obesity-associated pathways Type 2 diabetes glycemic regulation models Hepatic lipid metabolism and NAFLD/NASH research Cardiometabolic risk factor evaluation Receptor selectivity and tri-agonist pharmacology   Phase 2 data also demonstrated up to 82% reduction in liver fat in NASH-related research models. Also available from NeuroPept Labs: Retatrutide 30mg.   Product Specifications Specification Detail Peptide Name Retatrutide (LY3437943) Also Known As GLP-3RT, Triple G Agonist Format Lyophilized powder Amount 10mg per vial Purity 98% (HPLC verified) Storage -20°C or below, away from moisture and light Reconstitution Sterile bacteriostatic water (research use) Intended Use In vitro laboratory research only COA Verification freedomdiagnosticstesting.com   Storage and Handling   Store lyophilized peptide at -20°C or below prior to reconstitution Avoid repeated freeze-thaw cycles Protect from direct light, humidity, and room temperature exposure Reconstitute using sterile laboratory solvents under aseptic conditions Once reconstituted, store at 4°C and use within recommended timeframes   Frequently Asked Questions   What is Retatrutide 10mg? Retatrutide (LY3437943) is a synthetic 39-amino acid research peptide and triple receptor agonist targeting the GLP-1, GIP, and glucagon receptors simultaneously. It is studied for metabolic signalling, energy expenditure, hepatic fat metabolism, and receptor pharmacology research. Available from NeuroPept Labs in 10mg and 30mg vials.   What is the difference between Retatrutide 10mg and 30mg? Both vials contain the same research-grade Retatrutide peptide at 98% HPLC purity. The 10mg vial is suited for smaller-scale research protocols or initial dose-finding studies, while the 30mg vial provides a higher quantity for extended or larger-volume experiments.   How does Retatrutide differ from Tirzepatide? Tirzepatide is a dual GLP-1/GIP receptor agonist. Retatrutide adds a third target the glucagon receptor (GCGR) which introduces direct hepatic fat metabolism, lipolysis, and energy expenditure pathways not engaged by tirzepatide’s dual mechanism.     Scientific References Triple-Hormone-Receptor Agonist Retatrutide for Obesity Phase 2 Trial, NEJM 2023 Efficacy and Safety of Retatrutide PMC/NIH 2025 Triple Agonism Based Therapies for Obesity PMC/NIH 2025   Research Use Disclaimer: All products sold by NeuroPept Labs are intended strictly for in vitro laboratory research and scientific investigation by qualified professionals. They are not approved for human consumption, medical treatment, or veterinary use. Purchasers are responsible for compliance with applicable regulations in their jurisdiction.